J&J halts sale of electric fibroid removal devices

Johnson & Johnson is halting sales of devices used to remove growths in the uterus following a government warning that the electronic surgical tools can inadvertently spread cancer to other parts of the body.

The announcement comes one week after the Food and Drug Administration discouraged doctors from using the devices, known as laparoscopic power morcellators. Surgeons use the devices to treat painful fibroids, either by removing the growths themselves or the entire uterus. The morcellators shred the tissue so it can be removed through a small incision in the abdomen.

The FDA said there is a significant risk that the devices can grind up undetected uterine tumors, spreading the to the pelvis and other regions.

J&J says its three power morcellators have always included language about this risk.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Fibroids are common problem for women

Apr 01, 2014

Uterine fibroids are very common, occurring in as many as 50 percent of women in their reproductive years and up to two-thirds of women by the time they go through menopause. While many fibroids cause no problems and require ...

FDA reviews DNA-based colon cancer screening kits

Mar 24, 2014

The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests which use DNA from a patient's stool to detect dangerous tumors and growths.

Study ties breast gene to high-risk uterine cancer

Mar 24, 2014

Women with a faulty breast cancer gene might face a greater chance of rare but deadly uterine tumors despite having their ovaries removed to lower their main cancer risks, doctors are reporting.

Recommended for you

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.